Company: ALAR
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0001213900-25-025287
Chunk: 75

Company: Alarum Technologies Ltd.
Filing Date: 2025-03-20
Form: 20-F
Item: Item 5
Chunk 75
---
 Following final repayment of
the principal facility, the Company is entitled to all future revenue generated by the customers which were acquired using the strategic
funding. In consideration for said amendments of the O. R. B. agreement, O. R. B. was entitled to a total of $0.5 million.

As
of December 31, 2024, we received aggregate funding of $2.6 million and repaid to O. R. B. an amount of approximately $1.5 million from
the revenues that were generated as a result of the funding, and approximately $1.1 million is currently outstanding.

Shelf Registration Statement

On November 25, 2024, we filed
a shelf Registration Statement on Form F-3 (File No. 333-283429), or the F-3, which became effective on November 29, 2024. We may offer
and sell from time to time in one or more offerings up to a total amount of $100 million of ADSs. The current Form F-3 replaced the former
F-3, which expired on March 31, 2024.

Current Outlook

As of December 31, 2024, our
cash and cash equivalents and high rated long-term debt investments were approximately $25.0 million. We expect that our current resources
will be sufficient to meet our anticipated cash needs for the foreseeable future and at least for the next 12 months. Our operating plans
may change as a result of many factors that may currently be unknown to us, which may impact our funding plans. Our future capital requirements
will depend on many factors, including:

  the progress and costs of our research and development activities;                                                                                       
  the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally;  
  the scope of our general and administrative expenses; and                                                                                                

  potential future acquisitions.  

5. C Research and development, patents and licenses, etc.

For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see “ Item
5. Operating and Financial Review and Prospects - A. Operating Results - Operating Expenses” and “ Item 5. Operating
and Financial Review and Prospects - A. Operating Results - Comparison of the year ended December 31, 2023, to the year ended
December 31, 2022 - Research and Development Expenses